Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Oatly Group AB - ADR — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Oatly Group AB - ADR trades at $12.93 (market cap $415.98M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 71.2× Oatly Group AB - ADR's market cap, and Oatly Group AB - ADR is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | OTLY | |
|---|---|---|
Market Cap | $29.60B | $415.98M |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $18.54 |
52-Week Low | $205.48 | $8.03 |
Enterprise Value | $27.56B | $920.39M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Oatly (OTLY) trades at $13.23, up 0.84% today, with a bullish technical signal supported by moving averages and RSI. The company reported Q2 2026 revenue of $240.1 million, beating expectations, and raised its full-year outlook. However, it remains unprofitable with a net income margin of -13.81% and negative cash flow. Analyst sentiment is mixed with 44% buy ratings, 50% hold, and 6% sell.
Outlook hinges on revenue growth and margin improvements, but risks include high debt, persistent cash burn, and delayed profitability. The stock offers speculative upside if operational turnaround accelerates, yet investors face significant financial stability concerns amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
